Literature DB >> 20621520

Intravenous insulin therapy in the maintenance of strict glycemic control in nondiabetic acute stroke patients with mild hyperglycemia.

Jacek Staszewski1, Bogdan Brodacki, Jerzy Kotowicz, Adam Stepien.   

Abstract

Several reports indicate that mild hyperglycemia (plasma glucose level [PGL] ≥7.0 and ≤10.0 mmol/L [≥126 and ≤180 mg/dL]) is associated with poor prognosis in nondiabetic patients who sustain acute ischemic stroke (AIS). Insulin therapy to maintain PGL <7.0 mmol/L (<126 mg/dL) has been reported to be beneficial in critically ill patients, but the safety and efficacy of this approach in patients with AIS are not well established. In a prospective, open-label study, 50 consecutive nondiabetic patients with AIS admitted within 12 hours of ictus and with a PGL ≥7.0 and ≤10.0 mmol/L (≥126 and ≤180 mg/dL) were randomized to receive either a 24-hour intravenous (IV) insulin infusion (ISI) adjusted to maintain PGL within 4.5-7.0 mmol/L (81-126 mg/dL) (ISI group; n=26) or treatment with subcutaneous insulin if PGL was >10.0 mmol/L (>180 mg/dL) (control group [CG]; n=24). Patients' neurologic status was assessed based on National Institutes of Health Stroke Scale (NIHSS) score at admission, 24 hours and 30 days. The 2 groups did not differ in terms of risk factors for stroke. The mean PGL measured at admission was 8.25±0.9 mmol/L (149±16 mg/dL) in the ISI group and 8.1±0.8 mmol/L (146±14 mg/dL) in the CG (P=.8). After 24 hours, these values dropped to 4.9±0.5 mmol/L (88±9 mg/dL) and 5.5±0.45 mmol/L (99±8 mg/dL), respectively (P < .01). Two patients from the ISI group (8%) required IV glucose infusion for symptomatic hypoglycemia. There was no significant between-group difference in neurologic status at admission (median NIHSS score, 10±3 vs 10±2) and 24 hours later (8±2 vs 9±3). At 30 days, the median NIHSS score was 4±3 in the ISI group and 7±4 in the CG (P=.04). Our findings indicate that in nondiabetic AIS patients with mild hyperglycemia, IV insulin therapy aimed at maintaining strict glycemic control (PGL 4.5-7.0 mmol/L [81-126 mg/dL]) is relatively safe and may improve stroke outcome.
Copyright © 2011 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20621520     DOI: 10.1016/j.jstrokecerebrovasdis.2009.11.013

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  21 in total

Review 1.  Insulin resistance in ischemic stroke.

Authors:  Xiao-Ling Deng; Zhou Liu; Chuanling Wang; Yanfeng Li; Zhiyou Cai
Journal:  Metab Brain Dis       Date:  2017-06-21       Impact factor: 3.584

2.  Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality.

Authors:  N R Evans; K K Dhatariya
Journal:  Clin Med (Lond)       Date:  2012-04       Impact factor: 2.659

3.  Potential link between post-acute ischemic stroke exposure to hypoglycemia and hemorrhagic transformation.

Authors:  Kyle D Klingbeil; Sebastian Koch; Kunjan R Dave
Journal:  Int J Stroke       Date:  2017-11-14       Impact factor: 5.266

4.  Effects of Diabetes Mellitus and Admission Glucose in Patients Receiving Mechanical Thrombectomy: A Systematic Review and Meta-analysis.

Authors:  Guang-Dong Lu; Zi-Qi Ren; Jin-Xing Zhang; Qing-Quan Zu; Hai-Bin Shi
Journal:  Neurocrit Care       Date:  2018-12       Impact factor: 3.210

Review 5.  Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials.

Authors:  Tomohide Yamada; Nobuhiro Shojima; Hisashi Noma; Toshimasa Yamauchi; Takashi Kadowaki
Journal:  Intensive Care Med       Date:  2016-09-16       Impact factor: 17.440

6.  Impaired fasting glucose is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase.

Authors:  E Osei; S Fonville; A A M Zandbergen; P J Koudstaal; D W J Dippel; H M den Hertog
Journal:  J Neurol       Date:  2018-04-17       Impact factor: 4.849

7.  Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial.

Authors:  Karen C Johnston; Askiel Bruno; Qi Pauls; Christiana E Hall; Kevin M Barrett; William Barsan; Amy Fansler; Katrina Van de Bruinhorst; Scott Janis; Valerie L Durkalski-Mauldin
Journal:  JAMA       Date:  2019-07-23       Impact factor: 56.272

Review 8.  Glycemic variability and acute ischemic stroke: the missing link?

Authors:  Emmanuel I González-Moreno; Carlos R Cámara-Lemarroy; José G González-González; Fernando Góngora-Rivera
Journal:  Transl Stroke Res       Date:  2014-08-03       Impact factor: 6.829

9.  Analysis of the risk factors for the short-term prognosis of acute ischemic stroke.

Authors:  Jin Liang; Wenbo Liu; Jianping Sun; Xinyi Gu; Qiang Ma; Weijun Tong
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 10.  Effect of waivers of consent on recruitment in acute stroke trials: A systematic review.

Authors:  William B Feldman; Anthony S Kim; S Andrew Josephson; Daniel H Lowenstein; Winston Chiong
Journal:  Neurology       Date:  2016-03-23       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.